Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Nathan Bahary

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0005-3900-816X; OpenAlex author ID A5073785005. Sources: ClinicalTrials.gov.

Their work

Papers
58 (first author 4, last author 6)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
2
Collaborators
233
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 2 papers · 2012: 1 paper · 2013: 4 papers · 2014: 2 papers, 1 trial · 2015: 5 papers · 2016: 2 papers · 2017: 6 papers, 1 trial · 2018: 10 papers · 2019: 1 paper · 2020: 7 papers · 2021: 8 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 50 of 58

  1. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  2. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. First author DOI 10.1093/oncolo/oyae210↗
  3. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323↗
  4. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP … Co-author DOI 10.1016/j.esmoop.2023.101584↗
  5. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.hpb.2022.12.002↗
  6. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.01.016↗
  7. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltrat… Co-author DOI 10.1158/1078-0432.ccr-23-0535↗
  8. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  9. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  10. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  11. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… Co-author DOI 10.1002/jso.26267↗
  12. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26510↗
  13. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  14. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  15. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09446-x↗
  16. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  17. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗
  18. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Last author DOI 10.3389/fonc.2021.678070↗
  19. Patterns of Failure After Adjuvant Stereotactic Body Radiation Therapy for Pancreatic Cancer With Close or Positive Margins. Co-author DOI 10.1016/j.adro.2020.08.006↗
  20. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. First author DOI 10.1158/1078-0432.ccr-19-4042↗
  21. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  22. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08094-0↗
  23. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08468-9↗
  24. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗
  25. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  26. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  27. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy. Co-author DOI 10.1002/cncr.31242↗
  28. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  29. Autophagy Inhibition in Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.clcc.2017.10.013↗
  30. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resecta… Co-author DOI 10.1016/j.prro.2017.10.001↗
  31. A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned. First author DOI 10.1089/jpm.2017.0113↗
  32. Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age. Co-author DOI 10.1155/2018/2380596↗
  33. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. Last author DOI 10.1186/s12967-018-1562-z↗
  34. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancrea… Co-author DOI 10.1200/jco.2017.74.9564↗
  35. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Co-author DOI 10.1245/s10434-018-6521-7↗
  36. Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation. Co-author DOI 10.3389/fonc.2018.00052↗
  37. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. Co-author DOI 10.1186/s12957-017-1240-2↗
  38. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Co-author DOI 10.1245/s10434-016-5707-0↗
  39. Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival. Co-author DOI 10.1245/s10434-017-5975-3↗
  40. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. Last author DOI 10.21037/jgo.2017.01.23↗
  41. A margin distance analysis of the impact of adjuvant chemoradiation on survival after pancreatoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2017.04.02↗
  42. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.6004/jnccn.2017.0058↗
  43. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-instituti… Co-author DOI 10.1007/s11605-016-3256-2↗
  44. Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Co-author DOI 10.1097/mpa.0000000000000439↗
  45. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  46. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and develop… Co-author DOI 10.1097/mpa.0000000000000298↗
  47. Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1200/jco.2014.55.7504↗
  48. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.2015.62.8719↗
  49. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-015-4566-4↗
  50. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage I… Co-author DOI 10.1016/j.pan.2014.07.003↗

Trials 3

  1. Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Principal investigator NCT03344172↗
  2. hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Principal investigator NCT02960594↗
  3. A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreati… Principal investigator NCT01181245↗

Closest collaborators

The 25 strongest of 233 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 28 shared papers, 2013–2023 · strength 2.80
  2. Herbert J. Zeh · 33 shared papers, 2011–2022 · strength 2.62
  3. Aatur Dilip Singhi · 21 shared papers, 2014–2023 · strength 2.13
  4. Melissa Ellen Hogg · 17 shared papers, 2014–2022 · strength 1.57
  5. Alessandro Paniccia · 11 shared papers, 2019–2023 · strength 1.36
  6. Brian A. Boone · 13 shared papers, 2013–2022 · strength 1.20
  7. Michael T. Lotze · 9 shared papers, 2015–2023 · strength 0.92
  8. David L. Bartlett · 10 shared papers, 2011–2021 · strength 0.82
  9. Samer S. AlMasri · 5 shared papers, 2021–2023 · strength 0.73
  10. Ibrahim Nassour · 5 shared papers, 2021–2023 · strength 0.68
  11. Caroline J. Rieser · 6 shared papers, 2018–2023 · strength 0.66
  12. Zev A. Wainberg · 3 shared papers, 2024–2026 · strength 0.58
  13. Paul E. Oberstein · 4 shared papers, 2018–2026 · strength 0.52
  14. Ignacio Garrido‐Laguna · 3 shared papers, 2023–2024 · strength 0.51
  15. Randall E. Brand · 6 shared papers, 2013–2022 · strength 0.43
  16. Steven A. Burton · 6 shared papers, 2012–2020 · strength 0.43
  17. Erkut Hasan Borazanci · 3 shared papers, 2018–2024 · strength 0.42
  18. Pranav Murthy · 3 shared papers, 2020–2023 · strength 0.37
  19. Christos K Fountzilas · 2 shared papers, 2024 · strength 0.36
  20. Asmita Chopra · 3 shared papers, 2021 · strength 0.36
  21. Dwight Earl Heron · 5 shared papers, 2012–2020 · strength 0.36
  22. Eileen Mary O'Reilly · 4 shared papers, 2014–2026 · strength 0.36
  23. Adam C. Olson · 3 shared papers, 2020–2021 · strength 0.33
  24. Andrew Eugene Hendifar · 4 shared papers, 2017–2021 · strength 0.32
  25. Amr I. Al Abbas · 3 shared papers, 2018–2020 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.